Back to Results

PharmaCyte Biotech Inc (PMCB)

PharmaCyte Biotech Inc. is a NASDAQ-listed common stock issuer in the biotechnology sector that focuses on developing cellular therapies for cancer. The company’s work centers on its Cell-in-a-Box platform, a proprietary cellulose-based live cell encapsulation technology designed for use in cancer treatment research and commercialization efforts, including applications in advanced and inoperable pancreatic cancer. PharmaCyte Biotech also develops CypCaps for pancreatic cancer and other solid tumors. The company has cooperation and license agreements related to the use of its technology with Iroquois Master Fund Ltd., SG Austria Pte. Ltd., and Austrianova Singapore Pte. Ltd. Originally incorporated in 1996 and formerly known as Nuvilex, Inc., it adopted the PharmaCyte Biotech name in January 2015 and is based in Las Vegas, Nevada.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-PMCB
$0.65
41.3% Upside
Undervalued
Not available
Not available
Fair
0.0%
0.2x
4.922 M
-23.701 M
0.0%
93.8%
2.5
-2.0%
19.1%
Valuation • Fair Value

PharmaCyte Biotech Inc (NASDAQ-PMCB) Fair Value by Valuation Model

Review the available estimates for PharmaCyte Biotech Inc (NASDAQ-PMCB), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.65

Estimated upside of 41.3% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.65

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for PharmaCyte Biotech Inc (NASDAQ-PMCB) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for PharmaCyte Biotech Inc (NASDAQ-PMCB)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review PharmaCyte Biotech Inc (NASDAQ-PMCB) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for PharmaCyte Biotech Inc (NASDAQ-PMCB)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Altman Z-Score

2.5

Intermediate risk zone.

FCF / Net Income

19.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for PharmaCyte Biotech Inc (NASDAQ-PMCB). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for PharmaCyte Biotech Inc (NASDAQ-PMCB)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

Payout Ratio

-2.0%

Dividend payout reference.

How to read events and dividends

The latest data indicates no current dividend yield for PharmaCyte Biotech Inc (NASDAQ-PMCB). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

PharmaCyte Biotech Inc (NASDAQ-PMCB) Stock Forecast & Technical Outlook

Review PharmaCyte Biotech Inc (NASDAQ-PMCB) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for PharmaCyte Biotech Inc (NASDAQ-PMCB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for PharmaCyte Biotech Inc (NASDAQ-PMCB) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for PharmaCyte Biotech Inc (NASDAQ-PMCB) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for PharmaCyte Biotech Inc (NASDAQ-PMCB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for PharmaCyte Biotech Inc (NASDAQ-PMCB) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for PharmaCyte Biotech Inc (NASDAQ-PMCB)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, PharmaCyte Biotech Inc (NASDAQ-PMCB) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

PharmaCyte Biotech Inc (NASDAQ-PMCB) Stock FAQ

Data-supported answers about PharmaCyte Biotech Inc (NASDAQ-PMCB), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.65
Estimated upside 41.3%
Valuation Rating
Undervalued
Estimated upside of 41.3%
Financial Health
Fair
Current financial-health read

The current fair value estimate for PharmaCyte Biotech Inc (NASDAQ-PMCB) is $0.65. This implies an estimated upside of 41.3% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 41.3% versus the current market price.

The current financial health read for PharmaCyte Biotech Inc (NASDAQ-PMCB) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for PharmaCyte Biotech Inc (NASDAQ-PMCB).

The current market capitalization listed for PharmaCyte Biotech Inc is 4.922 M.

The current enterprise value listed for PharmaCyte Biotech Inc is -23.701 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for PharmaCyte Biotech Inc is NASDAQ-PMCB, and the stock is listed on NASDAQ.

PharmaCyte Biotech Inc (NASDAQ-PMCB) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for PharmaCyte Biotech Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for PharmaCyte Biotech Inc is 93.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B